Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(18 sites)

United States

Galderma Investigational Site (site# 8893), Birmingham, Alabama

Galderma Investigational Site (site# 8130), Los Angeles, California

Galderma Investigational Site (#9975), Sacramento, California

Galderma Investigational Site (site# 8021), San Diego, California

Galderma Investigational Site (site# 7075), San Francisco, California

Galderma Investigational Site (#8295), Miami, Florida

Galderma Investigational Site (site# 7054), Tampa, Florida

Galderma Investigational Site (site# 8142), Indianapolis, Indiana

Galderma Investigational Site (site# 8743), Ann Arbor, Michigan

Galderma Investigational Site (site# 8521), Saint Joseph, Missouri

Galderma Investigational Site (site# 8108), Las Vegas, Nevada

Galderma Investigational Site (site# 7110), New City, New York

Galderma Investigational Site (site# 7111), Fargo, North Dakota

Galderma Investigational Site (#8212), Portland, Oregon

Galderma Investigational Site (#8255), Philadelphia, Pennsylvania

Galderma Investigational Site (site# 8003), Webster, Texas

Galderma Investigational Site (site# 8862), Fairfax, Virginia

Galderma Investigational Site (site# 8725), Morgantown, West Virginia